Tim Lowinger

Company: Mersana

Job title: Chief Scientific Officer

Seminars:

Delving into XMT-1660, XMT-1592 & the Dolasynthen Platform 4:30 pm

Outlining how the Dolasynthen platform is a fully homogeneous, defined platform compatible with multiple site specific bioconjugation technologies Highlighting the opportunity Dolasynthen provides to precisely create ADCs with DARs ranging from 2 to 18+ with full homogeneity Providing details on the Dolasynthen ADCs XMT-1660 targeting B7H4 and XMT-1592, targeting NaPi2bRead more

day: Day Two